drugset / Trial / NCT00236548
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
Phase 3
Completed
1 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen, LP · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the usefulness of the Risperdal® Consta® Treatment Guidebook in helping the doctor switch the adult patient from taking risperidone tablets daily by mouth to taking long-acting risperidone by injection. The study will also evaluate the effectiveness and safety of long-acting risperidone and its effect on patient satisfaction.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2003-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | 2 mg | Oral |
| Subject | Risperidone | Other / unclassified | 6 mg | Oral |
| Subject | Risperidone | Other / unclassified | 25 mg | Oral |
| Subject | Risperidone | Other / unclassified | 37.5 mg | Oral |
| Subject | Risperidone | Other / unclassified | 50 mg | Oral |